News | January 04, 2012

Gene Analysis Helps Identify Basis of Rare Infant Heart Disorder

January 4, 2012 - A study reported in the current issue of Pediatric and Developmental Pathology compares cardiac tissue from 12 patients with histiocytoid cardiomyopathy (HC) and 12 age-matched controls. Researchers found differences in gene expression that could indicate a predisposition for HC.

HC typically occurs in the first two years of life. It affects females three times more often than males, leading to the theory that it is an X chromosome-linked disorder, with prenatal death occurring in males. Eighty percent of the cases occur in whites 15 percent in blacks and 3 percent in Latin Americans. It is very rare in those of Asian heritage.

A worldwide registry of HC was started in 1999, attempting to identify the gene responsible for the fatal disorder. These data have shown a family tendency for HC.

The gene analysis undertaken in the current study found decreased protein expression, or downregulation, in two sets of genes aligned sequentially along the genome. This offers several genes as candidates for the mutation, possibly predisposing individuals to HC.

The downregulation of a particular gene could result in reduced survival of cardiac myocytes, leading to cardiac failure during a baby’s development. These candidate genes will now offer a starting point for further research into inherited patterns of mutation. Utilizing the HC registry, researchers will seek to confirm the findings of this study and to collect and analyze blood from parents and siblings of HC patients in an effort to further expose the inheritance pattern.

 Full text of the article, “Identification of Candidate Genes for Histiocytoid Cardiomyopathy (HC) Using Whole Genome Expression Analysis: Analyzing Material from the HC Registry,Pediatric and Developmental Pathology, Vol. 14, No. 5, 2011, is available at http://www.pedpath.org/doi/full/10.2350/10-05-0826-OA.1

For more information: www.pedpath.org

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now